Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018

Characteristics Associated with Negative Interferon-γ Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013–2015

Duc T. Nguyen, Larry D. Teeter, Julie Graves, and Edward A. GravissComments to Author 
Author affiliations: Houston Methodist Research Institute, Houston, Texas, USA (D.T. Nguyen, E.A. Graviss); Forensic Research and Analysis, Portland, Oregon, USA (L.D. Teeter); University of Medicine and Health Sciences, New York, New York, USA (J. Graves); University of Texas School of Public Health, Houston (J. Graves)

Main Article

Table 5

Cox proportional hazards model for association between 1-year survival from tuberculosis treatment start date and characteristics of culture-confirmed TB patients with negative IGRA results, by IGRA type, Texas, USA, 2013–2015*

All IGRA results, N = 1,343† QFT only, n = 880† T-SPOT.TB only, n = 463†
aHR (95% CI)
p value

aHR (95% CI)
p value

aHR (95% CI)
p value
Negative IGRA result 2.12 (1.24–3.63) 0.01 1.84 (0.98–3.47) 0.06 3.41 (1.18–9.88) 0.02
Age in years 1.06 (1.04–1.07) <0.001 1.06 (1.04–1.07) <0.001 1.05 (1.02–1.09) 0.002
Alcohol use 1.42 (0.82–2.48) 0.21 1.57 (0.85–2.93) 0.15 1.06 (0.30–3.80) 0.92
HIV positive 4.68 (2.40–9.12) <0.001 4.60 (2.26–9.34) <0.001 2.75 (0.32–23.40) 0.36
Time from diagnosis to treatment 0.99 (0.99–1.00) 0.002 0.99 (0.99–1.00) 0.01 0.99 (0.98–1.00) 0.10

*aHR, adjusted hazard ratio; IGRA, interferon-γ release assay; QFT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis.
†Cox proportional hazards models were run with data from patients having complete data sets for all the included variables; aHRs were from the multivariate Cox proportional hazards models.

Main Article

Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.